Condition: Locally Advanced Pancreatic Adenocarcinoma · Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma. The study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen.
This description comes directly from the study's public registry record.
Aurore MOUSSION, MD · 0467612446 · Aurore.Moussion@icm.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Paoli Calmettes | Marseille, Bouches-du-Rhône, France | Recruiting |
| CHU Carémeau | Nîmes, Gard, France | Recruiting |
| CHU Saint-Eloi | Montpellier, Herault, France | Recruiting |
| Institut régional du Cancer de Montpellier | Montpellier, Hérault, France | Recruiting |
| Hôpital Beaujon | Clichy, France | Not Yet Recruiting |
| Centre Georges-François Leclerc | Dijon, France | Recruiting |
| Hôpital Pitié Salpétriêre | Paris, France | Recruiting |
| Centre Eugène Marquis | Rennes, France | Not Yet Recruiting |
| Hopital Paul Brousse | Villejuif, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04570943